Drug recall · May 24, 2023
Lorazepam Injection recall
Why: Failed Impurities/Degradation Specifications: Out-of-specification results for total related compounds observed during retain steting due to the elevated Related Compound-C.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Lorazepam Injection, USP, 2mg/mL, 1 mL vial (NDC 0641-6044-01), packaged in 25 x 1 mL Vials per carton (NDC 0641-6044-25), Rx only, Manufactured by West-Ward, Eatontown, NJ 07724.
- Lots / codes
Lots: 070086, 070128, Exp. 07/2023
- Quantity
- 1,352,475 vials
- Company
- Hikma Pharmaceuticals USA Inc., Cherry Hill, NJ
- Distribution
- Nationwide in the USA and Puerto Rico
- Initiated
- May 11, 2023 · Voluntary: Firm initiated
- Classified
- May 15, 2023
- Reported
- May 24, 2023
- Ended
- December 12, 2023
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Lorazepam
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.